Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calcium, vitamin D health claim draft guidance

This article was originally published in The Tan Sheet

Executive Summary

Health claims that calcium and vitamin D may reduce the risk of osteoporosis must clarify that adequate intake is essential to reduce osteoporosis risk. However, claims may not imply adequate intake is the only risk factor for developing osteoporosis, FDA says in a May 14 draft small entity compliance 1guidance. Beginning Jan. 1, 2010, food marketers may make health claims that calcium and vitamin D reduce the risk of osteoporosis if they comply with a final rule published in November 2008 (2"The Tan Sheet" Oct. 6, 2008, p. 16)

You may also be interested in...



FDA Adds Vitamin D To Osteoporosis Risk Reduction Health Claim

Bone-health claims may be made for vitamin D when the nutrient is combined with calcium, according to an FDA final rule

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS102957

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel